A New Convenient Oral Alternative
The need to help diabetes patients and patients with metabolic syndrome manage their disease is significant. Current treatments, which target only diabetes, are far from ideal, ranging from oral drugs and injections that enhance insulin sensitivity and output to injected insulin.
These therapeutic approaches are fraught with challenges to the patient and to the medical profession. A major problem with currently used drugs for diabetes is that all of them have side effects, some very serious, which have led to restrictions in their use. Furthermore, those drugs are not fully effective and their efficacy wanes over time. Additionally, most of them do not address insulin resistance, which leads to many comorbidities including CV and NASH. The result is the need to use combinations of two or more drugs to control diabetes. Some of the newer, more effective drugs are injectable, and therefore inconvenient to administer and expensive to manufacture.
BioKier’s novel product will be an oral tablet, in the non-prescription class, and will restore gut hormone secretion in patients who need to improve insulin sensitivity and manage their glucose better.
Based on the known properties of GLP-1 and its metabolites, our innovative approach promises to be beneficial to the cardiovascular system, is expected to lower triglycerides, and also reduce weight.